Mandibular Advancement Device on Sleep Quality in Obstructive Sleep Apnea Patients (DAMOSA)
Impact of Treatment With Mandibular Advancement Device (MAD) on Sleep Quality in Patients With Obstructive Sleep Apnea (OSA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28004
- Maria Fernanda Troncoso Acevedo
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of Obstructive Sleep Apnea Syndrome
- opt for mandibular advancement device as 1st treatment alternative
- opt for mandibular advancement device due to intolerance to continuous positive airway pressure
Exclusion Criteria:
- Patient with orthodontics, malocclusion and periodontal or temporomandibular joint disease who, after assessment by dentistry contraindicates it.
- Central Sleep apnea (more than 50% of central events in the baseline polygraph).
- Under 18 years old.
- Pregnancy
- Comorbidities that can potentially alter sleep architecture.
- Psychophysical inability to complete questionnaires.
- Not obtaining informed consent.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mandibular advancement device on sleep quality
Time Frame: 3 years
|
Tolerability and efficacy of treatment with a mandibular advancement device (MAD) on sleep quality in patients with Obstructive Sleep Apnea (OSA) measured by the ambulatory circadian monitoring device.
|
3 years
|
|
ambulatory circadian monitoring device
Time Frame: 3 years
|
To evaluate improvement in sleep quality with mandibular advancement devices measured by fragmentation and stability of sleep by the circadian monitoring sensor.
|
3 years
|
|
home sleep apnea test
Time Frame: 3 years
|
To evaluate the number of residual apneic breaths measured by home home sleep apnea test
|
3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Obstructive sleep apnea severity
Time Frame: 3 years
|
Evaluate the severity by home sleep apnea test
|
3 years
|
|
questionnaire SF-12
Time Frame: 3 years
|
multidimensional health related quality of life
|
3 years
|
|
questionnaire EuroQoL
Time Frame: 3 years
|
standardized non-disease specific instrument to describe and value health-related quality of life
|
3 years
|
|
questionnaire iPAQ
Time Frame: 3 years
|
International Physical Activity Questionnaire
|
3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PI19/00830
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.